METHOD FOR PREDICTION OF RISK OF LUMINAL BREAST CANCER PROGRESSION
	BALKANOV A S; MIKHAYLOV I V; ROSANOVA C A
	2024-05-31
专利权人	MOSC REGIONAL SCI-RES CLINICAL INST (MORE-Non-standard)
申请日期	2024-05-31
专利号	RU2836845-C1
成果简介	NOVELTY - Invention refers to medicine, namely to oncology, and can be used to predict the risk of progression of luminal breast cancer with diameter of not more than 3 cm. Immunohistochemical analysis of histological preparations prepared from patient’s tumour samples is carried out to determine the number of T-lymphocytes CD8+, number of T-lymphocytes CD4+ and number of M2 macrophages CD163. In cells of the invasive edge of the primary tumour, expression of CD4+, CD8+ and CD163 is determined. If the expression of CD163 is less than 20%, and the sum of the expression of CD4 and CD8 is less than 15%, a low risk of progression is predicted. If CD163 is more than or equal to 20%, and the sum of CD4 and CD8 expression is less than 15%, an average risk of progression is predicted. If CD163 is more than or equal to 20%, and the sum of CD4 and CD8 expression is more than or equal to 15%, a high risk of progression is predicted. USE - Medicine. ADVANTAGE - Method provides higher prediction accuracy, possibility of predicting a strictly defined molecular subtype of breast cancer at early stages by analysing the indicators of the proposed complex of tumour-associated markers with the assessment of the main subpopulations of infiltrating T-lymphocytes and the level of tumour-infiltrating M2 macrophages. 1 cl, 5 ex
IPC 分类号	C07K-016/30 ; G01N-033/574
国家	俄罗斯
专业领域	生物科学
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/16481
专题	中国科学院新疆生态与地理研究所
作者单位	MOSC REGIONAL SCI-RES CLINICAL INST (MORE-Non-standard)
推荐引用方式 GB/T 7714	BALKANOV A S,MIKHAYLOV I V,ROSANOVA C A. METHOD FOR PREDICTION OF RISK OF LUMINAL BREAST CANCER PROGRESSION. RU2836845-C1[P]. 2024.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。